Drug Profile


Alternative Names: Depromel; Fluvoxamine maleate; Luvox; Luvox CR; SME-3110

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer Abbott Laboratories; AbbVie; Jazz Pharmaceuticals plc; Meiji Seika Pharma
  • Class Antidepressants; Oximes; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Obsessive-compulsive disorders; Social phobia

Most Recent Events

  • 01 Aug 2016 AbbVie completes phase-III clinical trials in Obsessive-compulsive disorders (In adolescents; In children) in Japan (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 19 Jan 2015 Fluvoxamine is still in phase III trials for Obsessive-compulsive disorders (in paediatric patients) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top